Pharmacokinetics of quinolones: Newer aspects
Authors:
- 1 April 1991
- journal article
- review article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 10 (4) , 267-274
Abstract
Differences in pharmacokinetic properties are emerging as important determinants in distinguishing among clinical uses of individual new quinolone antimicrobial agents. Selected data on pharmacokinetics, new pharmacokinetic studies, and pharmacodynamics are reviewed, with reference to norfloxacin, ciprofloxacin, ofloxacin, pefloxacin, enoxacin, fleroxacin, lomefloxacin, and other new quinolones. Considering pharmacokinetics, oral bioavailability is excellent (>95 %) for most quinolones. Differences in peak serum concentrations and β-half-lives of elimination exist, however, and are reflected in up to ten-fold differences in values of the area under the curve of serum concentration versus time for administration of similar drug doses. As suggested by high apparent volumes of distribution and low binding to serum proteins, penetration into many body tissues and fluids is favorable. Considering new findings, orally administered ciprofloxacin has been found to be absorbed primarily in the duodenum and jejunum. Studies also suggest this drug to be cleared by transpithelial elimination into the bowel lumen as well as by the renal route. Oral bioavailability of quinolones has been demonstrated to be in general good in ill as well as healthy subjects but is reduced on co-administration with magnesium- and aluminum-containing acids, sucralfate (which contains aluminum), or ferrous sulfate. Pharmacodynamic parameters, such as the relationship of serum concentrations and drug potency in vitro to clinical response and suppression of bacterial resistance, have been little studied and merit further investigation.Keywords
This publication has 80 references indexed in Scilit:
- Serum levels of ciprofloxacin after single oral doses in patients with septicemiaEuropean Journal of Clinical Microbiology & Infectious Diseases, 1989
- Multicenter in vitro evaluation of lomefloxacin (NY-198, SC-47111), including tests against nearly 7,000 bacterial isolates and preliminary recommendations for susceptibility testingDiagnostic Microbiology and Infectious Disease, 1988
- The Quinolones: An Overview and Comparative Appraisal of Their Pharmacokinetics and PharmacodynamicsThe Journal of Clinical Pharmacology, 1988
- IntroductionClinical Infectious Diseases, 1988
- Pharmacokinetics and tissue penetration of orally administered pefloxacinEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- RO 23-6240 (AM-833), a new fluoroquinolone: In vitro antimicrobial activity and tentative disk diffusion interpretive criteriaDiagnostic Microbiology and Infectious Disease, 1987
- OfloxacinDrugs, 1987
- Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administrationEuropean Journal of Clinical Microbiology & Infectious Diseases, 1986
- Evaluation of in vitro antibacterial activity of enoxacin: Comparison with other orally absorbed antimicrobial agents, proposed disk diffusion test interpretive criteria, and quality control limitsDiagnostic Microbiology and Infectious Disease, 1985
- Pharmacokinetics of norfloxacin in healthy volunteers and patients with renal and hepatic damageEuropean Journal of Clinical Microbiology & Infectious Diseases, 1983